A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01064752
Recruitment Status : Completed
First Posted : February 8, 2010
Last Update Posted : February 8, 2010
Information provided by:
University of California, San Francisco

Brief Summary:
This will be an uncontrolled, open-labelled pilot study exploring whether minocycline has a measurable and selective effect on HIV infection of the central nervous system.

Condition or disease Intervention/treatment
HIV Infection Drug: Minocycline

Detailed Description:

This study is founded on a sequence of related hypotheses: 1. inflammatory responses related to activation of macrophages importantly contribute to the magnitude of CNS HIV infection by increasing the local production of viral progeny; 2. the tetracycline, minocycline, has anti-inflammatory properties which likely underlie studies showing that this drug can inhibit HIV-1 infection in macrophages and microglia in vitro and reduce simian immunodeficiency virus (SIV) encephalitis in macaques; 3. by reducing CNS monocyte/macrophage/microglial activation, minocycline will therefore reduce CNS HIV infection; 4. CSF will reflect or parallel (and thus serve as a 'model' of) brain infection and inflammation in this setting; 5. therefore, longitudinal CSF monitoring can assess the effect of minocycline on both CNS HIV infection and inflammation; 6. because the brain injury underlying AIDS dementia complex (ADC) and its pathological substrate, HIV encephalitis, critically involve inflammatory processes and, in the broad sense, immunopathology, minocycline might eventually prove useful as an adjunct to antiviral therapy in accelerating recovery from this condition (though importantly, this pilot study will not include ADC patients).

This will be an uncontrolled, open-labelled pilot study exploring whether minocycline has a measurable and selective effect on CSF HIV RNA concentration. There are no previous studies examining this effect in humans. We define a priori a 'biologically meaningful' effect to be an increase in the Δplasma-CSF HIV concentration of >0.5 log10 copies/mL of HIV RNA (i.e. an increase in the difference between plasma and CSF of >0.5 log10 copies/mL of HIV RNA compared to the baseline difference) in the face of unchanged or reduced plasma HIV RNA. Reductions in the absolute levels of CSF and plasma HIV as well as reductions in CSF inflammatory markers and T cell activation will also be of interest.

This study will serve as an initial exploration of the possible therapeutic effect of minocycline on CNS HIV infection. Our overall strategy is to begin with this pilot study, and if the results look promising (biological effect and lack of toxicity), to use these results to design a controlled trial, either as a single or multi-institutional study.

Additionally, this study shares an almost identical design with another proposed study examining the effects of atorvastatin on CSF HIV infection. While neither of these studies is controlled, they will yield pilot comparative results.

Study Type : Observational
Actual Enrollment : 7 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Pilot Study of the Effect of Minocycline on Cerebrospinal Fluid HIV-1 Infection
Study Start Date : April 2005
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Group/Cohort Intervention/treatment
HIV-1 infected, not on anti-retroviral medication
Drug: Minocycline
100 mg po bid for 8 weeks

Biospecimen Retention:   Samples With DNA
Samples of both cerebrospinal fluid and blood will also be frozen and stored.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
HIV-infected subjects >18 years old not on antiretroviral therapy who are willing to volunteer to take minocycline and undergo the four study LPs and other evaluations recruited from the San Francisco Bay area.

Inclusion Criteria:

  1. HIV infection with plasma and CSF HIV RNA concentrations (using Roche Amplicor assay) > 1,000 copies/ mL (available after baseline LP).
  2. Off antiretroviral therapy (ART) for > 6 weeks before the study and no plans to begin treatment for the study duration. (The decision of whether or not a subject takes antiretroviral therapy will be made by the subject in consultation with his/her primary care provider prior to screening for this study.)
  3. Predicted adherence to the medication.
  4. Capable of providing informed consent.
  5. > 18 years old
  6. CD4 cell counts >150 cells/μL (though likely most, if not all, will be >250 cells/μL).
  7. When available, subjects will be screened for stability of blood CD4 and HIV RNA levels.

Exclusion Criteria:

  1. Taking a tetracycline within 6 months or history of adverse reaction to minocycline or another tetracycline.
  2. Enhanced risk from lumbar puncture, including documented or suspected cerebral mass lesion predisposing to brain herniation or bleeding diathesis.
  3. Pregnancy or expectation of pregnancy during the study.
  4. Active opportunistic infection or active neurological disease that might confound evaluation.
  5. ADC Stage > 1.
  6. Hemoglobin < 10 Gms/dL.
  7. BUN or creatine above the normal limits.
  8. Taking other drugs known to reduce the metabolism of minocycline and thus increase the probability of toxicity.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01064752

Sponsors and Collaborators
University of California, San Francisco
Principal Investigator: Richard W Price, MD University of California, San Francisco

Responsible Party: Richard W. Price, MD, University of California San Francisco Identifier: NCT01064752     History of Changes
Other Study ID Numbers: H9133-26156-04
First Posted: February 8, 2010    Key Record Dates
Last Update Posted: February 8, 2010
Last Verified: April 2009

Keywords provided by University of California, San Francisco:
Immune activation
Cerebrospinal fluid

Additional relevant MeSH terms:
Communicable Diseases
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Anti-Bacterial Agents
Anti-Infective Agents